RBC downgrades Coloplast over guidance cut, strategy uncertainty

Coloplast A/S

09/05/2025 12:13

** RBC cuts Coloplast COLOb.CO to "sector perform" from "outperform" and PT by 26% to DKK 700 following the Danish medical equipment maker's guidance cut

** The broker lowers its FY expectations for Interventional Urology, citing issues that have not fully resolved, and Ostomy Care

** It also cites uncertainty ahead of a new strategy in the absence of a permanent CEO after Kristian Villumsen stepped down on May 5

** It lowers its growth and margin forecast, leading it to cut its EPS estimate by 10% for 2025/26 as it anticipates headwinds to continue

** Out of 24 analysts that cover Coloplast, five rate the stock "strong buy" or "buy,"​ 17 rate it "hold" and two​ "strong sell" or "sell"

 (Reporting by Anna Chaberska)

 ((Anna.chaberska@thomsonreuters.com;))